Literature DB >> 15816620

Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT).

Yasuhiro Ito1, Hiroshi Yoshida, Chisato Tomoda, Takashi Uruno, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Kanji Kuma, Akira Miyauchi.   

Abstract

BACKGROUND: The recent availability of a monoclonal antibody against human telomerase reverse transcriptase (hTERT) has enabled us to investigate the telomerase activity of tissue specimens more easily than by classical TRAP assay. In this study, we studied teromerase activity in thyroid tumors using this antibody.
MATERIALS AND METHODS: We immunohistochemically investigated hTERT expression in 166 thyroid neoplasms.
RESULTS: Normal follicular cells did not express hTERT. In papillary carcinoma, high hTERT expression was observed in 34.5% of cases and it was directly linked to stage and the presence of lymph node metastasis. In follicular carcinoma, 39.2% were classified as the high hTERT expression group, showing a significantly higher incidence than that in follicular adenoma, 9.8%. In anaplastic carcinoma, 73.7% were regarded as the high hTERT expression group, which was larger than the percentages in papillary and follicular carcinomas. We investigated the diagnostic usefulness of hTERT measurement for discriminating follicular carcinoma from adenoma. Its specificity and positive predictive value were high at 90.2% and 83.3%, respectively, while the sensitivity and negative predictive value were low.
CONCLUSION: These results suggest that: i) telomerase activity contributes to anaplastic transformation of differentiated carcinoma and ii) hTERT measurement may contribute to diagnosing follicular carcinoma, but whether it can be applied to preoperative diagnosis by fine-needle aspiration biopsy specimens remains unclear.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816620

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Authors:  Yongchun Wang; Jeanne Kowalski; Hua-Ling Tsai; Radharani Marik; Nijaguna Prasad; Helina Somervell; Pang-Kuo Lo; Lauren E Sangenario; Lars Dyrskjot; Torben F Orntoft; William H Westra; Alan K Meeker; James R Eshleman; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

2.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

Review 3.  TERT promoter mutations in thyroid cancer.

Authors:  Rengyun Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2016-01-05       Impact factor: 5.678

4.  MicroRNA Role in Thyroid Cancer Development.

Authors:  Francesca Marini; Ettore Luzi; Maria Luisa Brandi
Journal:  J Thyroid Res       Date:  2011-05-10

5.  Nuclear-specific accumulation of telomerase reverse transcriptase (TERT) mRNA in TERT promoter mutated follicular thyroid tumours visualised by in situ hybridisation: a possible clinical screening tool?

Authors:  L Samuel Hellgren; Ann Olsson; Ann Kaufeldt; Johan O Paulsson; Martin Hysek; Adam Stenman; Jan Zedenius; Catharina Larsson; Anders Höög; C Christofer Juhlin
Journal:  J Clin Pathol       Date:  2021-05-19       Impact factor: 4.463

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.